�e ijĬİĩ

ĺłʼnőŏĩļŊŏʼnńłŎ ňŊʼnĩŀŅōŅłŌŃŇĩĽŌłʼnŎ ĩıįİijƴ±¦Ûr·ĢEƴĩ

ÄËs�F:�ƲĊ+,sƳĩ ĸ�ðĹĩ

u ^ĩ Ĕ¡0ÈMSÏ]·!$£!ÈSĩ

  8ĩ Ĕ_=Čĩ

Ä Ë ƗƱƦĩƨƔƤƫƖƎƑƯƚƮƱƧưOPħëBä¸Ŵ ċŵ$Q��ô�ű�ò¢¹

tµŵėºĩ

ĩ

�ðŵ�sŶç³ŰŧŞŕÄË,sF:űťůcFĂ�Ŵ}ĈŤƄźŧªƇţ´nŠŬŤŚŖÄË

¾¼ŕÄËv¤ŕÄËs�ųŲƇ İ ƣƱƒŴźűŽůŠŬŤŚŖƲ@íŕ"ÁųŲŵā�Ƈ9żƳĩ

: R

catechol-o-methyltransferase(COMT) m

(Nature 2008 Kanasaki et al) 2

0

0

20 2

2 0 COMT

COMTưOPħëBä¸Ŵ ċŵ$Q�

�Űřƃű�ûťŕCOMT20

- COMT r o

COMT estradiol2-methoxyestradiol(2-ME) 2-ME

β 0 1

ÄËv¤ :ĩ ƨƔƤƫƖƎƑƯƚƮƱƧƩƘƬ.¬űťůħãàĤ(ƎƊƖƎƟƈƖƙ: fat energy 32%)ĩ x�C57Bl6 ƦƋƓƇ²ŚūŖCOMTĚXé(Ro41-0960)ŕCOMT siRNAŕmetforminx�WĦŴęťůŶÃ�ĘơƮƙƐƱƬ(2 ĎĘ)Ƈŕ2-ME qkx�WĦŴęťůŶ 10 ĎĘħãàĤx�Ƈ²Śŕ2-ME ŵx�Ŷ�hŵ 4ĎĘŵŻìŭūŖåæβÐáŝƁŵƊƯƓƫƯ$£ŶƦƋƓβÐáƪƊƯMIN6ÐáƇ²ŚūŖOPħëBä¸ŶëÍ�.k¬ăŴZŧƃ�B3jď­pŰřƃŖŪŢŰŕƉƯƍƌƗƯƑƯ

II(AII)|Ó½�¥[ŴZŧƃ�B3jŴŜšƃ COMT ��Ŝƀŷ 2-ME ¢¹-�ŵ�õžìŭūŖ

ÄËÒ�ƹĩ ŘCOMT -01 0 : ① (10 ) C57BL6 20 COMT

2-ME( 6 4 ) - ②2-MEAMPK ③metformin COMT

metformin AMPK COMT ④22 2-ME 10

4 2-ME⑤MIN-6 0 A in vitro 2-ME

2-ME β ⑥ COMTCOMT 2-ME

COMT ⑦COMTc m II 2-ME

2-ME AII-1 2-ME (2-hydroxyestradiol: COMT ) 0 ⑧2-ME PPARγ

ÜY :ĩ �öÒ�ŝƁ COMT Ş�ŗų°H?QŴƀƂº®Ş��ŧƃê»ŰřƃŪŵ��ŞOPħëBä¸-ƨƔƤƫƖƎƑƯƚƮƱƧŴ ċŵ$Q�¼Űřƃ5âkŞÆ;ŤƄūŖĩ

COMT 2-ME

�e ijĬıŒĩ

ĺłʼnőŏĩļŊŏʼnńłŎ ňŊʼnĩŀŅōŅłŌŃŇĩĽŌłʼnŎ ĩıįİijƴ±¦Ûr·ĢEƴĩ

ÄËs�F:�ƲĊ+,sƳĩ ĸ÷ÐĹĩ

u ^ĩ Ĕ¡0ÈMSÏ]·!$£!ÈSĩ

  8ĩ Ĕ_=Čĩ

Ä Ë ƗƱƦĩƨƔƤƫƖƎƑƯƚƮƱƧưOPħëBä¸Ŵ ċŵ$Q��ô�ű�ò¢¹

tµŵėºĩ

ĩ

¾¼ĮÄË�¤ĮÒ�ĮÜYĮ hŵýģųŲĪIJ ƣƱƒ�!Ƴĩ

o catechol-o-methyltransferase(COMT) mRNAhaplotype 0 COMT

0 COMT 2 2-methoxyestradiol (2-ME)

COMT r o 0 Kanasaki et al. Nature 20080 DBA-2J dahl-salt sensitive o spontaneously hypertensive o

COMT 0

COMT m

0

m

EstradiolCYP450hydroxyestradiol(2OH-E)

2OH-E m

m o 2OH-E COMT 2-methoxyestradiol (2-ME) ( 1) 2-ME hypoxia-inducible factor (HIF)-1α

2

0 COMT m 0

( HIF-1α ) 2-MECOMT o COMT

COMT

1: 2 COMT 2: Ï�Ā¶aŴŜŚů COMT ��ŞžūƁŧgğűŪŵ$Q��ŵô� 3: AII mĄ�B3jŴŜšƃ COMT ��ŵę�ű$Q�dŵô�

�� 1: %��$�-')/ COMT ���� ���0��*/ �{ 1: COMT Ŷ�ŗų°H?QŴƀƂŪŵê»ƭƢƬŕmRNA UVkŞJ/ŧƃŞÂƁƄƃŖ WĦ 1-1: 8 C57Bl6 (Quick Fat) 10 2 COMT

western blot , mRNA PCR 1-1: COMT ( 2A,B)

COMT mRNA A 0 A 2C 1-1: COMT

COMT 5 N

metformin COMT 1-2 ĩ

@ 2ĩ ħãàĤx�Ŵƀƃßæ COMT 껺®��

�e ijĬıœĩ

¾¼ĮÄË�¤ĮÒ�ĮÜYĮ hŵýģųŲĪIJ ƣƱƒ�!Ƴĩ

1-2:10 4 metformin 0 COMT

Ò� 1-2: metformin x�ŴƀƂßæ COMT 껺®Ŷ�a/ťŕmRNA º®ŶħãàĤŕmetformin x�ŧŸůŵÙŰèJƇùŽųŝŭū(@ 2A-C)Ŗ ÜY 1-2: ħãàĤŴƀƃ COMT þÎ��Ŵ mRNA º®ƭƢƬŶę�ũŨŕĆ"hþÎ��ŵRCƇÆ;ťūŖŪŢŰ COMT þÎ��Ŵę�ŧƃűÜśƁƄƃ microRNA Ŵ¥¾ťūŖ WĦ 1-3: �aĤŕħãàĤŕħãàĤ+metformin x�Ùŵßæ microRNA array ô�ƇìŚŕCOMT þÎŵ�î microRNA ƇƓƎƫƱƜƯƏťūŖmicroRNA array Ŷ Agilent Ç release version 15 Ƈ²ŚūŖ Ò� 1-3: humanCOMT3’UTRŴŶŕmicroRNA30cŵÒ6Ē%ŞRCŧƃŖƦƋƓ microRNA arrayô�ŰŶŕ@ 3 ŵ�Ŵ microRNA30c ŞħãàĤŰ��ťŕmetformin ŴƀƂ�a/ťū(@ 3)Ŗƞƙ!½ÐáƇ²Śū�õŴŜŚůž microRNA30c Ŷ metformin x�ŴƀƂ��ťūŖ ÜY - hŵýģ 1: ƞƙ COMT 3’UTR Ŷ�ŴƎƮƱƜƯƏŞÑ�ťŕ h metformin x�ſmicroRNA30c Ƈ9ŽūŪŵ��{ŵřƃ microRNA ƇÔؼŴô�ťŕCOMT껺®þÎ��Ƈ microRNA Ŵƀƃ'iŝƁ�õŧƃŖūŬť COMT3’UTR ŵ microRNA ŴƀƃþÎ��ŶÉŴƀŭů¿ĐŞřƃžÜśƁƄƃŖ�Ŵŕmouse COMT 3’UTR ž7�Ŵ�õŧƃŖ �� 2: COMT "(��!-�&/�#,+.����0��*/ �{ 1:ĩ ƊƯƓƫƯzykƇOP&�Ŵ�ŧƃ¸�ŶūűśëÏŞ�aŰřŭůžŕ

ŪŵhOPħëBä¸Ƈº¸ťſŧŚŖź

ūŕOPħëBä¸Ƈ�ťūNkŶŕŪŵ

hŵ�±ŰÏ]·º¸ƫƓƎŞħŚŞ

ÂƁƄůŚƃŖŢƄƁŵÒ�ŶŕOPħë

Bä¸-Ï�Ā¶aŵĘŵ·p±¯ŴŜšƃƎƮƓƙƱƎƇÆ;ťŕŪŵ$Q��ű

ťů COMT ��ŵnÚƇ�õťūŖ WĦ 2-1: ĩ 2COMT (Ro-41-0960 25µg/kg/day)

A 2-1: COMT

i

R COMT 2-ME2-ME

0 A 0 A COMTCOMT siRNA A 5

2-1: ( 2-2)

2-2 (10 ) 2-ME (6 4 2-ME 10ng/day s.c. ) A

2-2: 10 20 6 2-ME 4 A

R R 2-ME2 0 2-ME

3

ÜY 2-2: 2-MEŶħãàĤ�ŵëÏ~>-�ŴŜŚůŕÃ�ŰŶƊƯƓƫƯ$£Ƈ�ťůŕĖ�ŴŶƊƯƓƫƯzykƇ~>ŧƃ5âkŞřƃŖ WĦ 2-3: metformin x��ŴŜšƃ COMT ĚXŵnÚƇ�õťūŖ

Ò� 2-3: metformin ŴƀƂßæ COMT껺®Ş�a/ŧƃ(@ 2)ŖmetforminŶßæ AMPKŵƫƯē/Ƈú\ťŕëÏƇ~>ťū(@ 4A-C)Ŗmetformin x��+COMT 20

AMP-activated protein kinase (AMPK) 2 ( 4 A,B) 2-ME ĩ

@ 3: Ė�ħãàĤx�ƦƋƓŴ 2-ME ŞÏ�ĀŴžūƁŧ-�

�e ijĬıŔĩ

¾¼ĮÄË�¤ĮÒ�ĮÜYĮ hŵýģųŲĪIJ ƣƱƒ�!īĩ

AMPK ( 4

A,B) metformin

A ( 4 E,F) COMT

2-ME ( 4 B-G)

2-3: metforminCOMT/2-ME

2-4: COMT± 2-ME ( 10 )

Ò� 2-4: OPƦƋƓűĝOPƨƓƦƋƓŵßæ COMT 껺®Ƈ�ć�õťūűŢƅŕßæ COMTê»ŶOPƦƋƓŰ�nŴ��ťůŚūŖCOMT ĚXéx�ŴƀƂÞÏâŶl/ŕƊƯƓƫƯ���Ƈ�ŭūŖ2-ME ŴƀƂßæ AMPK ¦k/ŕÞÏâ~>űë�ƊƯƓƫƯ���ƇùŽūŖ ÜY 2-4: 7Ŧ COMTĚXéx�ŴƀƃÞÏâl/ŕ2-MEŴƀƃ~>ŰžWĦƩƘƬŴƀƂŕƊƯƓƫƯ$£Ŵ2ŹŧgğŶ¶ųŭūŖßæ AMPK ¦k/ŰŶWĦ 2-1,2-3 ŴñƁƄƃ 2-ME ŴƀƃƊƯƓƫƯ$£)©�²Ŷû�ŰşŨŕβÐáŴZŧƃ 2-ME T×WĦƇìŭū(WĦ 2-5)Ŗ WĦ 2-5: ƦƋƓβÐáƪƊƯŰřƃ MIN6 ÐáŴ 2-MEŕmetformin ŵT×WĦƇìŭūŖ Ò� 2-5: MIN6ŝƁŵƊƯƓƫƯ$£Ŷ 2-MET×ŰI+ŕmetforminT×ŰŶJ/ŞųŝŭūŖ2-MEŴƀƂ MIIN6ÐáŰŵ AMPK Ŷ¦k/ťūŞŕmetformin ŰŶùŽųŝŭūŖAMPK siRNA ƝƖƎƕƋƯWĦƇìŚŕ2-MEŴƀƃMIN6ÐáŝƁŵƊƯƓƫƯ$£I+ŶAMPK�RkŰřƃƇñ#ťūŖťŝťųŞƁŕAMPK ¦k/é AICAR ŵŻŰŶƊƯƓƫƯ$£I+ŶÅùŤƄŨŕAMPK ¦k/ŵŻŰŶƊƯƓƫƯ$£ú\ޱŦųŝŭūŖŪŢŰŤƁųƃ�õƇìŭūűŢƅ 2-ME ŴƀƂÐá±RƑƏƛƬŰřƃ PDX1 ŵ¦k/űƉƥƙƱƑƓú\űęčŧƃ MST1 ŵw'ŞÅùŤƄū ÜY - hŵýģ 2: �WĦÒ�ŝƁÜśƃűŕmetformin ŴƀƃëÏ~>-�Ŷ COMT Ŵ�RťůŜƂŕx�&�ŶβÐáŵ�â~>Ƈ�ťůŚƃ5âkŞřƃŖCOMTđ�QLDűmetformin3jkŵĘŴ¿ęŞřƃ5âkŞřƃŖ2-ME ŴƀƃβÐá±RƑƏƛƬ¦k/Ŷ hŵÏ]·¢¹tµėºŴŮųŞƃŖ �� 31 COMT ( AII -�*/���� 0�*/�� 0��*/ WĦ 3: COMT ĚXéx��«ŴŜŚů|Ó¼AII ½�x�(700ng/kg/day)ŵ�B3jŕ2ŷ2-ME 2ŷ 2-ME ŵ*ĥ¬ă 2OH-E (010ng/day) 0 A

3 AII( 6) COMT

AIIR COMT +AII 20

2OH-E A

2-ME ( 5) 2-ME PPARγ AII-15 AII

ÜY - hŵýģ 3: OPħëBä¸ŰŶ AII ŴZŧƃ�Bo4kŞďťůŜƂŕCOMT ��ŞŪŵ·pŵ�pŰřƃ5âkŞřƃŖ®C siRNA x�ƦƋƓŰž�Ŵ�õťůŚƃŖ*ĉŵ

microRNA30c ŶƞƙOPħëBä¸Űë�ƭƢƬŞ��ťůŜƂŕOP� COMT ��ŞžūƁŧ AII�Bo4kďŴę�ťůŚƃ5âkŞřƃŖAII Ŷ«ÿƨƔƤƫƖƎƑƯƚƮƱƧŴĕűųƃëÍ�.k$QŰřƂŕCOMT ��ŶëB'iŵĞŝƁž ċŵ$Q��Űřƃ5âkŞřƃŖĩ

@ 4ƹmetformin ŴƀƃëÏ~>ű COMT

@ 5 COMT ĚXŶ AII Ŵƀƃ�Bo4kƇmĄťŕ2-ME ŶCOMTĚXŴƀƂmĄťūo4kƇw'ŧƃŞŕ2OH-EŶw'ťųŚ

�e ijĬIJŒĩ

ĺłʼnőŏĩļŊŏʼnńłŎ ňŊʼnĩŀŅōŅłŌŃŇĩĽŌłʼnŎ ĩıįİijƴ±¦Ûr·ĢEƴĩ

ÄËs�F:�ƲĊ+,sƳĩ ĸºíWÖĮ�V�óĹĩ

u ^ĩ Ĕ¡0ÈMSÏ]·!$£!ÈSĩ

  8ĩ Ĕ_=Čĩ

ĩİ ĭ ÿ�ºíWÖĩ

  }Ĉb�ġƲ�ťŚžŵŝƁƳŴö�ŧƃŢűŖūŬťŕ�ÄË,sĔ��hŵžŵŴěƃŖĩ

  ÿ� ĿĻļ §�řƂűųťŴ$šůƫƓƙƇ�sŵŢűŖĩ

  èÝ8ŕÿ�8ŕ}Ĉø8ŕ`ŕ�&ű�hŵĠŕºíbĪï�īŕ�üŵ�«ŴŮŚůö�ŧƃŖ

ųŜŕèÝ8ŶÀµũŨŕ�ůƇö�ťŕç$ŵ8*Ŵ�ÕƇfŠŖĩ

  A!KĜøƇ<ƆųŚŖĩ

  1(�Ŷ ňʼnĩŋŌŅōō űö�ŕS�ŵƉƠƓƙƪƎƙŜƀŷxÊ�ŵÿ�Ŷ9ŽųŚŖĩ

  �ŞąƂųŚG6ŶŕIſťůö�ŧƃŢűŖĩ

Œ ƺÿ� ĿĻļ §�řƂƻĩ

Ƶĩ

Y. Takagaki, D. Koya, ※K.Kanasaki, Dipeptidyl peptidase-4 inhibition and renoprotection: the role of antifibrotic effects. Curr Opin Nephrol Hypertens. 26(1):56-66. (2017) Ʋ�üřƂƳ ĩ

ƶĩS.P. Srivastava, S. Shi, M. Kanasaki, T. Nagai, M. Kitada, J. He, Y. Nakamura, Y. Ishigaki, K.Kanasaki, D. Koya, Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis, Sci Rep, 6, 29884. (2016) Ʋ�üřƂƳĩ

ƷĩS. Shi, K.Kanasaki, D. Koya, Linagliptin but not Sitagliptin inhibited transforming growth factor-beta2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition, Biochem Biophys Res Commun, 471, 184-190. (2016) Ʋ�üřƂƳĩ

ƸĩN. Ueki, S. Takeda, D. Koya, K.Kanasaki, The relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsia, Int J Endocrinol, 2015, 572713. (2015) Ʋ�üřƂƳĩ

ĴĩS. Shi, S.P. Srivastava, M. Kanasaki, J. He, M. Kitada, T. Nagai, K. Nitta, S. Takagi, K.Kanasaki, D. Koya, Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition, Kidney Int, 88 ,479-489. Ʋ�üřƂƳĩ

œ ĸÿ� ĿĻļ §�ųťĹĩ

ƵĩK. Nitta, S. Shi, T. Nagai, M. Kanasaki, M. Kitada, S.P. Srivastava, M. Haneda, K.Kanasaki, D. Koya, Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen, Biomed Res Int, 2016: 9172157. (2016) Ʋ�üřƂƳĩ

ƶĩM. Kitada, Y. Ogura, T. Suzuki, S. Sen, S.M. Lee, K.Kanasaki, S. Kume, D. Koya, A very-low-protein diet ameliorates advanced diabetic nephropathy through autophagy induction by suppression of the mTORC1 pathway in Wistar fatty rats, an animal model of type 2 diabetes and obesity, Diabetologia, 59 , 1307-1317. (2016) Ʋ�üřƂƳĩ

Ʒĩ

K.Kanasaki, Concerted efforts to combat diabetic complications, Kidney Int, 89, 269-271. (2016) Ʋ�üųťƳĩ

ĩ

S. Kato, S. Maruyama, H. Makino, J. Wada, D. Ogawa, T. Uzu, H. Araki, D. Koya, K.Kanasaki, Y. Oiso, M. Goto, A. Nishiyama, H. Kobori, E. Imai, M. Ando, S. Matsuo, Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial, Clin Exp Nephrol, 19, 1098-1106. (2015) Ʋ�üřƂƳĩ

ĩ

S. Shi, D. Koya, ※K.Kanasaki, Dipeptidyl peptidase-4 and kidney fibrosis in diabetes, Fibrogenesis Tissue Repair, 9, 1. (2016) Ʋ�üřƂƳ

ĩ

�e ijĬIJœĩĩ

ı ĭ S�ºíWÖĩ

  ºíbġƲ�ťŚžŵŝƁƳŴö�ŧƃŢűŖūŬťŕ�ÄË,sĔ��hŵžŵŴěƃŖĩ

  ºíS�8ŕºíÝ8ŕ¨ģƇö�ŧƃŖĩ

  ƉƠƓƙƪƎƙŕơƮƏƪƧÌŵ ĿĻļ Ƈ§�ŧƃŢűŖĩ

  A!KƇ<ƆųŚŖĩ

  �ŞąƂųŚG6ŶŕIſťůö�ŧƃŢűŖĩ

ĩ ºí��ĩ ºíS�8ŕºíÝ8ŕ¨ģĩ

Ƶĩ

ıįİĵ b İı �ĩ 28 i microRNAĩ

ƶĩ

ıįİĵ b İİ �ĩ 46

ĩ

Ʒĩ

ıįİĵ b ĵ �ĩ 61 , 2 ĩ

Ƹĩ

ıįİĴ b ķ �ĩ 36 COMTĩ

Ĵĩ

ĩ

ĩ

ĩ

ĩ ĩ

IJ ĭ xÊŕºí�VƲxÊ�ŵÿ�ž9ŽƃƳĩ

ĩ xÊĮºí��ĩ Ĝø8ŕS�8Ìĩ

Ƶĩ ıįİĶ b ı �ĩ ľőŋŅŌŎŅʼnōňŊʼnĩ

ƶĩ

ıįİĶ b ı �ĩ ŁŃňŅʼnŎňņňŃĩŌŅŋŊŌŎōĩĪŌŅŐňōŅīĩ

Ʒĩ

ıįİĶ b Ĵ �ĩ ��Ï]·S�ĩ

Ƹĩ

ıįİĶ b Ĵ �ĩ ��äæS�ĩ

ĩ

ıįİĶ b ĵ �ĩ ��y+Ĩ0S�ĩ

ĩ

ĩ ĩ

ĩ

ĩ